NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

$92 Million Bet On This Penny Stock? Also Check Out Other 3 Stocks Under $5 Insiders Are Buying

Published 19/08/2022, 13:15
© Reuters.  $92 Million Bet On This Penny Stock? Also Check Out Other 3 Stocks Under $5 Insiders Are Buying
IXIC
-
HBIO
-
SMMT
-
MDRR
-
REIT
-

U.S. initial jobless claims dropped by 2,000 to 250,000 the week ended August 13th. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3

OncoCyte

  • The Trade: IN8bio, Inc. (NASDAQ: INAB) President, CEO and Chairman Taiwei William Ho bought a total of 26,315 shares at an average price of $1.90. To acquire these shares, it cost around $50 thousand.
  • What’s Happening: IN8bio recently posted a Q2 loss of $0.38 per share.
  • What OncoCyte Does: IN8bio Inc is a clinical-stage biotechnology company.
Harvard Bioscience
  • The Trade: Harvard Bioscience, Inc. (NASDAQ: HBIO) CEO James Green acquired a total of 40,000 shares at an average price of $3.19. The insider spent around $127.6 thousand to buy those shares.
  • What’s Happening: The company recently released Q2 results.
  • What Harvard Bioscience Does: Harvard Bioscience Inc is a US-based developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development.
U.S. Stock Futures Down Ahead Of Earnings; Crude Oil Drops

Don’t forget to check out our premarket coverage here .

Summit Therapeutics

  • The Trade: Summit Therapeutics Inc. (NASDAQ: SMMT) CEO Robert W Duggan acquired a total of 94,849,203 shares at an average price of $0.97. To acquire these shares, it cost around $92 million.
  • What’s Happening: Summit Therapeutics recently posted a Q2 loss of $0.17 per share.
  • What Summit Therapeutics Does: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases.
Medalist Diversified REIT
  • The Trade: Medalist Diversified REIT, Inc. (NASDAQ: MDRR) CFO C. Brent Winn acquired a total of 50,000 shares at an average price of $0.90. The insider spent $45.07 thousand to buy those shares.
  • What’s Happening: Alfred Lee Finley, last month, disclosed a 10.9% passive stake in Medalist Diversified REIT.
  • What Medalist Diversified REIT Does: Medalist Diversified REIT Inc is engaged in the acquisition, reposition, renovation, leasing and managing of income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties and hotel properties.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.